Article Per Year (5 Year)
p-Index From 2020 - 2025
1.829
P-Index
This Author published in this journals
All Journal Jurnal Online Mahasiswa (JOM) Bidang Keguruan dan Ilmu Pendidikan Gontor AGROTECH Science Journal JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA JURNAL ILMIAH PETERNAKAN TERPADU JURNAL EKONOMI SAKTI (JES) Jurnal Ilmiah Edunomika (JIE) Jurnal AFAMEDIS Jurnal Perencanaan, Sains dan Teknologi (Jupersatek) Ezra Science Bulletin Jurnal Akademik Pengabdian Masyarakat Journal of Clinical Pharmacy and Pharmaceutical Science
Irma Susanti
Unknown Affiliation
Aerospace Engineering Agriculture, Biological Sciences & Forestry Arts Humanities Automotive Engineering Chemical Engineering, Chemistry & Bioengineering Chemistry Computer Science & IT Control & Systems Engineering Decision Sciences, Operations Research & Management Earth & Planetary Sciences Economics, Econometrics & Finance Education Engineering Health Professions Industrial & Manufacturing Engineering Languange, Linguistic, Communication & Media Mathematics Mechanical Engineering Medicine & Pharmacology Social Sciences Transportation Other

Published : 11 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : Journal of Clinical Pharmacy and Pharmaceutical Science

 1 
Narrative Review of Anti-Retrovirals Used in COVID-19 Treatment Aditya Sindu Sakti; Irma Susanti; Djati Wulan Kusumo
Journal Clinical Pharmacy and Pharmaceutical Science Vol. 3 No. 2 (2024): Oktober : Journal of Clinical Pharmacy and Pharmaceutical Science
Publisher : Prodi D3 Farmasi Politeknik Katolik Mangunwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.61740/jcp2s.v3i2.54

Abstract

The COVID-19 pandemic has necessitated the exploration of various therapeutic strategies, including the repurposing of existing antiviral drugs. This narrative review examines the use of anti-retroviral agents in the treatment of COVID-19, focusing on their mechanisms of action, efficacy, and safety profiles. Key antiretrovirals discussed include Remdesivir, Lopinavir/Ritonavir, Ribavirin, Oseltamivir, Favipiravir, and Sofosbuvir. These agents primarily act by inhibiting RNA-dependent RNA polymerase (RdRp), a critical enzyme in the replication cycle of SARS-CoV-2. Clinical trials and in vitro studies have provided mixed results regarding their effectiveness, with some agents showing promise in reducing mortality and improving recovery times, while others have demonstrated limited efficacy. The review highlights the urgent need for further clinical research to optimize antiviral regimens and improve patient outcomes in the ongoing battle against COVID-19.
Co-Authors Aditya Sindu Sakti Anisa Zulfa Fatihah Annisa Ariantika Ayuni Fitri Catur Setyabudi Dian Septinova Faradilla Sari Fuad Nur Azis Gharizah Raisa Aqila Kusumo, Djati Wulan Lailatul Nuraini Lazim N Lazim N M. Muflih Zaki Al-Hadi Mohammad Saeri Naning Saktyarini Novely Dwita Ramadhani Nur Alfa Ibrieza Nur Cahyani Puspita Sari, Dyah Rony, Zahara Tussoleha Sintya Shafa Qotrunnida Tintin Kurtini Tusamma Salsabiila